American Pharmaceutical Partners to Report 2004 First Quarter Financial Results and Host Conference Call on April 21, 2004.Business Editors SCHAUMBURG, Ill.--(BUSINESS WIRE)--April 12, 2004 American Pharmaceutical Partners, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :APPX APPX Appendix APPX Application eXcellence (4GL software development tool) ) announced today it will release its 2004 first quarter financial results on April 21, 2004. The company also said that Patrick Soon-Shiong, M.D., the company's Chairman, President and Chief Executive Officer, Nicole Williams, Executive Vice President and Chief Financial Officer, Derek Brown, Co-Chief Operating Officer, and Jeffrey Yordon, Co-Chief Operating Officer, will host an investor conference call that same day at 8:30 a.m. PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT (11:30 a.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) to review the company's financial results and operations. The conference call will be available to interested parties through a live audio Internet broadcast at www.appdrugs.com and www.companyboardroom.com. The call will also be archived and accessible at both sites for one year. About American Pharmaceutical Partners, Inc. American Pharmaceutical Partners, Inc. is a specialty drug company that develops, manufactures and markets injectable pharmaceutical products, focusing on the oncology, anti-infective and critical care markets. APP has acquired the exclusive North American rights to manufacture and market ABRAXANE(TM), a proprietary nanoparticle injectable oncology product that has completed Phase III clinical trials for metastatic breast cancer and for which the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. has granted "Fast Track" designation. The NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any submission was completed in March 2004. The company believes that it has established the only commercial scale protein-engineered nanoparticle manufacturing capability in the United States. For more information, visit APP's website at www.appdrugs.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion